PT1308170E - Composição seca de factor sanguíneo que compreende trealose - Google Patents
Composição seca de factor sanguíneo que compreende trealose Download PDFInfo
- Publication number
- PT1308170E PT1308170E PT03002147T PT03002147T PT1308170E PT 1308170 E PT1308170 E PT 1308170E PT 03002147 T PT03002147 T PT 03002147T PT 03002147 T PT03002147 T PT 03002147T PT 1308170 E PT1308170 E PT 1308170E
- Authority
- PT
- Portugal
- Prior art keywords
- trehalose
- blood factor
- factor composition
- dried blood
- stable
- Prior art date
Links
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 title abstract 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 title abstract 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 title abstract 2
- 229960000182 blood factors Drugs 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 102000008100 Human Serum Albumin Human genes 0.000 abstract 1
- 108091006905 Human Serum Albumin Proteins 0.000 abstract 1
- 230000003019 stabilising effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9501040.1A GB9501040D0 (en) | 1995-01-19 | 1995-01-19 | Dried composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1308170E true PT1308170E (pt) | 2008-12-26 |
Family
ID=10768253
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT03002147T PT1308170E (pt) | 1995-01-19 | 1996-01-19 | Composição seca de factor sanguíneo que compreende trealose |
| PT96900633T PT871476E (pt) | 1995-01-19 | 1996-01-19 | Composicao seca de factor sanguineo compreendendo trealose |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT96900633T PT871476E (pt) | 1995-01-19 | 1996-01-19 | Composicao seca de factor sanguineo compreendendo trealose |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US6649386B2 (pt) |
| EP (4) | EP2258402A3 (pt) |
| JP (1) | JP3898221B2 (pt) |
| KR (1) | KR100417593B1 (pt) |
| CN (1) | CN1152713C (pt) |
| AT (2) | ATE245442T1 (pt) |
| AU (1) | AU704317B2 (pt) |
| CA (2) | CA2671383C (pt) |
| DE (2) | DE69629209T2 (pt) |
| DK (2) | DK0871476T3 (pt) |
| ES (2) | ES2316658T3 (pt) |
| GB (1) | GB9501040D0 (pt) |
| PT (2) | PT1308170E (pt) |
| SI (1) | SI1308170T1 (pt) |
| WO (1) | WO1996022107A1 (pt) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7244824B2 (en) * | 1995-01-19 | 2007-07-17 | Quadrant Drug Delivery Limited | Dried blood factor composition comprising trehalose |
| US7253262B2 (en) * | 1995-01-19 | 2007-08-07 | Quandrant Drug Delivery Limited | Dried blood factor composition comprising trehalose |
| GB9501040D0 (en) * | 1995-01-19 | 1995-03-08 | Quadrant Holdings Cambridge | Dried composition |
| US6964771B1 (en) | 1995-06-07 | 2005-11-15 | Elan Drug Delivery Limited | Method for stably incorporating substances within dry, foamed glass matrices |
| US6632648B1 (en) * | 1996-05-14 | 2003-10-14 | Elan Drug Delivery Limited | Methods of terminal sterilization of fibrinogen |
| GB9616536D0 (en) * | 1996-08-06 | 1996-09-25 | Quadrant Holdings Cambridge | Co-amoxiclav dosage form |
| AUPO871997A0 (en) * | 1997-08-25 | 1997-09-18 | Csl Limited | Dried biologically or therapeutically active preparations |
| ES2541470T3 (es) * | 1999-02-22 | 2015-07-20 | University Of Connecticut | Formulaciones de factor VIII libres de albúmina |
| KR100927764B1 (ko) * | 2001-08-10 | 2009-11-20 | 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 | 트레할로오스 또는 말티톨과 금속 이온 화합물과의 회합물(會合物) |
| WO2005028496A2 (en) | 2003-09-12 | 2005-03-31 | Antigenics, Inc. | Vaccine for treatment and prevention of herpes simplex virus infection |
| AU2005228945B2 (en) | 2004-03-19 | 2010-09-30 | Baxter Healthcare S.A. | Factor IXa for the treatment of bleeding disorders |
| EP2168975A3 (en) | 2004-05-24 | 2012-01-11 | Genvault Corporation | Method of stably storing biomolecules in recoverable form |
| KR100624013B1 (ko) | 2004-06-25 | 2006-09-19 | 주식회사 녹십자홀딩스 | 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제 |
| US8133484B2 (en) | 2006-12-15 | 2012-03-13 | Lifebond Ltd | Hemostatic materials and dressing |
| EP2114379A2 (en) * | 2006-12-20 | 2009-11-11 | Bayer HealthCare LLC | Factor vii and viia compositions |
| EP1958618A1 (de) | 2007-02-15 | 2008-08-20 | Octapharma AG | Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren |
| EP2222315B1 (en) * | 2007-12-21 | 2013-04-24 | Inspiration Biopharmaceuticals, Inc. | Stabilized factor ix formulations containing trehalose |
| US11197916B2 (en) | 2007-12-28 | 2021-12-14 | Takeda Pharmaceutical Company Limited | Lyophilized recombinant VWF formulations |
| BRPI0821474B8 (pt) * | 2007-12-28 | 2021-05-25 | Baxalta GmbH | formulação farmacêutica líquida estável |
| EP2334792B1 (en) | 2008-09-12 | 2020-09-09 | GenTegra LLC | Matrices and media for storage and stabilization of biomolecules |
| EP2349314B1 (en) | 2008-10-21 | 2013-02-27 | Baxter International Inc. | Lyophilized recombinant vwf formulations |
| EP2385825B1 (en) | 2008-11-07 | 2018-10-10 | University of Connecticut | Factor viii formulations |
| BR112012015029A2 (pt) | 2009-12-22 | 2017-06-27 | Lifebond Ltd | matriz reticulada, método para controlar a formação de uma matriz, método ou matriz, método para vedar um tecido contra vazamento de um fluído corporal, agente hemostático ou vedante cirúrgico, composição para vedar um ferimento, uso da composição, composição para um veículo para entrega localizada de fármaco, composição para engenharia de tecido, e método para modificar uma composição |
| EP2732262A4 (en) * | 2011-07-13 | 2014-12-10 | Denator Ab | PROCESS FOR STABILIZING LIQUID BIOLOGICAL SAMPLES |
| CN102416171B (zh) * | 2011-12-06 | 2013-12-25 | 中国医学科学院输血研究所 | 高纯度凝血酶原复合物制品干热病毒灭活过程中的保护剂 |
| US9700486B2 (en) | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| SG11201604136PA (en) * | 2013-12-19 | 2016-07-28 | Crucell Holland Bv | Improved formulations for virosomes |
| EP3177317B1 (en) | 2014-08-04 | 2020-03-18 | CSL Limited | Factor viii formulation |
| US10568948B2 (en) | 2015-05-13 | 2020-02-25 | Agenus Inc. | Vaccines for treatment and prevention of cancer |
| CN107333750A (zh) * | 2017-06-11 | 2017-11-10 | 成都吱吖科技有限公司 | 一种长时血液细胞稳定剂 |
| JP2021522239A (ja) | 2018-04-26 | 2021-08-30 | アジェナス インコーポレイテッド | 熱ショックタンパク質結合ペプチド組成物およびその使用方法 |
| US11998654B2 (en) | 2018-07-12 | 2024-06-04 | Bard Shannon Limited | Securing implants and medical devices |
| US20220389082A1 (en) | 2019-07-04 | 2022-12-08 | CSL Behring Lengnau AG | A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii |
| WO2022099223A2 (en) | 2020-11-09 | 2022-05-12 | Takeda Pharmaceutical Company Limited | Purification of fviii from plasma using silicon oxide adsorption |
| WO2022261716A1 (en) * | 2021-06-16 | 2022-12-22 | Exopharm Limited | Aqueous formulations for preservation of extracellular vesicles |
| WO2024102796A2 (en) * | 2022-11-08 | 2024-05-16 | University Of Wyoming | Stabilization of biologics and human blood clotting factor viii in a dry state |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4361509A (en) | 1981-12-14 | 1982-11-30 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
| US4495175A (en) * | 1982-08-05 | 1985-01-22 | University Of Rochester | Preparation of highly purified human antihemophilic factor |
| WO1987000196A1 (en) * | 1985-07-09 | 1987-01-15 | Quadrant Bioresources Limited | Protection of proteins and the like |
| FI86885C (fi) | 1984-04-20 | 1992-10-26 | Genentech Inc | Foerfarande foer framstaellning av human rekombinantfaktor viii och nukleinsyrasekvenser och vektorer anvaend daertill |
| EP0182448A3 (en) | 1984-08-24 | 1987-10-28 | Genetics Institute, Inc. | Production of factor viii and related products |
| US4758657A (en) * | 1985-07-11 | 1988-07-19 | Armour Pharmaceutical Company | Method of purifying Factor VIII:C |
| US4806343A (en) * | 1986-03-13 | 1989-02-21 | University Of Southwestern Louisiana | Cryogenic protectant for proteins |
| CA1329760C (en) * | 1987-10-29 | 1994-05-24 | Ted C. K. Lee | Plasma and recombinant protein formulations in high ionic strength media |
| US4877608A (en) * | 1987-11-09 | 1989-10-31 | Rorer Pharmaceutical Corporation | Pharmaceutical plasma protein formulations in low ionic strength media |
| CA2051092C (en) * | 1990-09-12 | 2002-07-23 | Stephen A. Livesey | Method and apparatus for cryopreparation, dry stabilization and rehydration of biological suspensions |
| DE4111393A1 (de) * | 1991-04-09 | 1992-10-15 | Behringwerke Ag | Stabilisierte faktor viii-praeparationen |
| US5288853A (en) * | 1992-04-30 | 1994-02-22 | Alpha Therapeutic Corporation | Factor viii purification process |
| JP3905921B2 (ja) * | 1992-10-02 | 2007-04-18 | ジェネティクス インスチチュート リミテッド ライアビリティー カンパニー | 凝固第▲ｖｉｉｉ▼因子を含む組成物及びその製造方法並びに安定剤としての界面活性剤の使用方法 |
| SE504074C2 (sv) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
| WO1995003332A1 (en) * | 1993-07-23 | 1995-02-02 | Baxter International Inc. | Activated human factor viii and method of preparation |
| US5576291A (en) * | 1993-09-13 | 1996-11-19 | Baxter International Inc. | Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency |
| US5955448A (en) * | 1994-08-19 | 1999-09-21 | Quadrant Holdings Cambridge Limited | Method for stabilization of biological substances during drying and subsequent storage and compositions thereof |
| GB9501040D0 (en) * | 1995-01-19 | 1995-03-08 | Quadrant Holdings Cambridge | Dried composition |
| US7253262B2 (en) * | 1995-01-19 | 2007-08-07 | Quandrant Drug Delivery Limited | Dried blood factor composition comprising trehalose |
| US5804420A (en) * | 1997-04-18 | 1998-09-08 | Bayer Corporation | Preparation of recombinant Factor VIII in a protein free medium |
| ES2541470T3 (es) * | 1999-02-22 | 2015-07-20 | University Of Connecticut | Formulaciones de factor VIII libres de albúmina |
-
1995
- 1995-01-19 GB GBGB9501040.1A patent/GB9501040D0/en active Pending
-
1996
- 1996-01-19 DE DE69629209T patent/DE69629209T2/de not_active Expired - Lifetime
- 1996-01-19 ES ES03002147T patent/ES2316658T3/es not_active Expired - Lifetime
- 1996-01-19 EP EP10008828A patent/EP2258402A3/en not_active Withdrawn
- 1996-01-19 CN CNB961926600A patent/CN1152713C/zh not_active Expired - Lifetime
- 1996-01-19 CA CA2671383A patent/CA2671383C/en not_active Expired - Lifetime
- 1996-01-19 AT AT96900633T patent/ATE245442T1/de active
- 1996-01-19 AT AT03002147T patent/ATE413885T1/de active
- 1996-01-19 EP EP96900633A patent/EP0871476B1/en not_active Expired - Lifetime
- 1996-01-19 WO PCT/GB1996/000119 patent/WO1996022107A1/en not_active Ceased
- 1996-01-19 US US08/875,796 patent/US6649386B2/en not_active Expired - Lifetime
- 1996-01-19 ES ES96900633T patent/ES2202425T3/es not_active Expired - Lifetime
- 1996-01-19 PT PT03002147T patent/PT1308170E/pt unknown
- 1996-01-19 CA CA002210872A patent/CA2210872C/en not_active Expired - Lifetime
- 1996-01-19 DK DK96900633T patent/DK0871476T3/da active
- 1996-01-19 AU AU44540/96A patent/AU704317B2/en not_active Expired
- 1996-01-19 KR KR1019970704891A patent/KR100417593B1/ko not_active Expired - Lifetime
- 1996-01-19 JP JP52213396A patent/JP3898221B2/ja not_active Expired - Fee Related
- 1996-01-19 DE DE69637749T patent/DE69637749D1/de not_active Expired - Lifetime
- 1996-01-19 EP EP03002147A patent/EP1308170B1/en not_active Expired - Lifetime
- 1996-01-19 SI SI9630765T patent/SI1308170T1/sl unknown
- 1996-01-19 PT PT96900633T patent/PT871476E/pt unknown
- 1996-01-19 EP EP08010169A patent/EP1974741A1/en not_active Withdrawn
- 1996-01-19 DK DK03002147T patent/DK1308170T3/da active
-
2009
- 2009-02-13 US US12/371,459 patent/US7803911B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1308170E (pt) | Composição seca de factor sanguíneo que compreende trealose | |
| IT1276723B1 (it) | Formulazioni di analoghi dell'insulina | |
| DK0808641T3 (da) | Praktisk "aftagelig" åndedrætsmaske | |
| ES2136105T3 (es) | Preparacion farmaceutica y/o cosmetica. | |
| HUP9900881A3 (en) | 4,5-diaryl oxazole derivatives and pharmaceutical compositions containing them | |
| FI962952A7 (fi) | Delta 12,13-iso-taksolianalogit, niiden antineoplastinen käyttö ja nii tä sisältävät farmaseuttiset koostumukset | |
| IL88503A0 (en) | 2,2-difluorocyclopropylethane derivatives and insecticidal and acaricidal compositions containing the same | |
| NZ330360A (en) | 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents | |
| BG103968A (en) | Pharmaceutical antiviral composition containing glycirricinic acid and at least one protein with antiviral activity | |
| HUP9901336A3 (en) | Heteroaryl-substituted acryloylguanidine derivatives and medicinal composition thereof | |
| ZA916517B (en) | Optically active trialone derivatives and compositions | |
| EP0558645A4 (en) | Erythrocytes and thrombo-erythrocytes as target specific agents | |
| HU9402648D0 (en) | 3,4-dioxo-1-cyclobuten-1-yl-substituted (indolyl-alkyl)-pyridine- and -pyrimidine derivatives and antimigraine composition containing them as active componens | |
| IL85517A (en) | 3-(2-haloethyl)1,4-oxathiin and 2-(2-haloethyl)1,4-dithiin derivatives and pharmaceutical compositions containing the same | |
| ITMI932019A0 (it) | Composizione farmaceutica antivirale contenente la 2-ammino 4,6-dicloropirimidina e metisoprinolo | |
| EP0297510A3 (en) | Bornane-3-spiro-1'-cyclopentane derivatives and perfumery compositions containing them | |
| KR950026459U (ko) | 착탈식 신발주머니를 가진 어린이용 책가방 | |
| KR900016452U (ko) | 성냥갑의 적린 도포장치 | |
| PH24948A (en) | 2-(2,2-difluorocyclopropyl)-alkylester and use as insecticide and acaricide | |
| IL94658A0 (en) | 1,5-diazabicyclodiones and pharmaceutical compositions containing them | |
| ITMI930453A1 (it) | Composizione farmaceutica avente attivita' antiasmatica | |
| ITAN940061A0 (it) | Calzatura di peso limitato e di elevate capacita' traspiranti | |
| SE9203012D0 (sv) | Kaeppen "sven". promenadkaepp med laettmanoevrerad isdubb | |
| HU9802416D0 (en) | 4-dezoxi-10,11,12,13-tetrahydro-demicosin and pharmaceutical composition containing it | |
| ITAN940032V0 (it) | Calzatura di peso limitato e di elevate capacita' traspiranti |